Immuneering Corporation

IMRX Healthcare Biotechnology

Immuneering Corporation’s revenue for fiscal 2022 (year ended December 2022) was $317,000.00. In the quarter to June 2026, EPS grew 32.5% and free cash flow fell 74.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.59 0.05 −1.37%
Market cap
$235.5M
P/E
0.0×
Fwd P/E
−3.5×
Dividend yield
—
F-score
3/9
Altman Z
4.47
Beneish M
−6.35
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
19.47 32.45 17.50 24.00
Net Debt/EBITDA
7.73 10.07 12.58 14.96
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.26) (0.29) (0.23) (0.30)
Book value per Share
2.95 3.19 4.96 5.75
Free Cash Flow
(16.53) (18.51) (9.96) (11.98)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates